Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Hypertriglyceridemia: its etiology, effects and treatment.

Yuan G, Al-Shali KZ, Hegele RA.

CMAJ. 2007 Apr 10;176(8):1113-20. Review.

2.

Treating hypertriglyceridemia.

Holub BJ.

CMAJ. 2007 Sep 11;177(6):604; author reply 604-5. No abstract available.

3.

Treating hypertriglyceridemia.

Röggla G, Fasan M, Kapiotis S.

CMAJ. 2007 Sep 11;177(6):603; author reply 604-5. No abstract available.

4.

Treating hypertriglyceridemia.

Yavasoglu I, Kadikoylu G, Bolaman Z.

CMAJ. 2007 Sep 11;177(6):603-4; author reply 604-5. No abstract available.

5.

Management of hypertriglyceridemia.

Oh RC, Lanier JB.

Am Fam Physician. 2007 May 1;75(9):1365-71. Review.

6.
7.
8.

[Hypertricglyceridemia: prognostic impact and treatment options].

Custodis F, Laufs U.

Dtsch Med Wochenschr. 2011 Jul;136(30):1533-42. doi: 10.1055/s-0031-1272575. Epub 2011 Jul 25. Review. German.

PMID:
21789752
9.

Hypertriglyceridemia and cardiovascular risk reduction.

Jacobson TA, Miller M, Schaefer EJ.

Clin Ther. 2007 May;29(5):763-77. Review.

PMID:
17697898
10.

Clinical practice. Hypertriglyceridemia.

Brunzell JD.

N Engl J Med. 2007 Sep 6;357(10):1009-17. Review. No abstract available.

PMID:
17804845
11.

Hypertriglyceridemia.

Pejic RN, Lee DT.

J Am Board Fam Med. 2006 May-Jun;19(3):310-6.

12.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
13.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
14.

A risk factor for atherosclerosis: triglyceride-rich lipoproteins.

Malloy MJ, Kane JP.

Adv Intern Med. 2001;47:111-36. Review.

PMID:
11795072
15.

Bridging the gap in treatment options for patients with hypertriglyceridemia.

Underberg JA, Hays R.

J Fam Pract. 2007 Dec;56(12 Suppl New):S24-31. Review.

PMID:
18664339
16.

Management of hypertriglyceridemia in the diabetic patient.

Jialal I, Amess W, Kaur M.

Curr Diab Rep. 2010 Aug;10(4):316-20. doi: 10.1007/s11892-010-0124-4. Review.

17.

Hypertriglyceridemia: impact and treatment.

Goldberg IJ.

Endocrinol Metab Clin North Am. 2009 Mar;38(1):137-49. doi: 10.1016/j.ecl.2008.11.005. Review.

PMID:
19217516
18.

Hypertriglyceridemia: management of atherogenic dyslipidemia.

Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM.

J Fam Pract. 2006 Jul;55(7):S1-8.

PMID:
16822443
19.

Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.

Plaisance EP, Grandjean PW, Mahurin AJ.

Phys Sportsmed. 2009 Apr;37(1):11-9. doi: 10.3810/psm.2009.04.1678. Review.

PMID:
20048483
20.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165

Supplemental Content

Support Center